David L. Hallal
CEO & Chairman of the BoardMr. David L. Hallal is Chief Executive Officer of Scholar Rock, Inc. since April 27, 2025 and serves as its Chairman of the Board of Directors since July 2017. He had been its Executive Chairman since April 2025. He served as Chairman and Chief Executive Officer of ElevateBio LLC until April 2025. He is CEO of Scholar Rock Holding Corporation from April 27, 2025 and has been its Chairman since July 2017 and serves as its Director since 2017. Mr. Hallal is Independent Chairman of the Board at Kalaris Therapeutics, Inc. since September 2018. He was Chief Executive Officer at Kalaris Therapeutics, Inc. since September 2018 to May 2021. He serves as President of Vanqua Bio, Inc. He served as Lead Independent Director of Seer, Inc. since September 2020 until August 2024. Mr. Hallal served as a Director of Seer, Inc. since February 2018 until July 07, 2025. Mr. Hallal served as Chairman of the Board at iTeos Therapeutics, Inc. since June 2018 until August 29, 2025. He serves as the Director at LifeEDIT, LLC. He co-founded in ElevateBio, LLC December 2017. He has been Director of AlloVir, Inc. since September 2018. Mr. Hallal served as Chairman of Allovir, Inc. since September 2018 until May 17, 2021 and has been its Executive Chairman since May 17, 2021 and had been its Chief Executive Officer since September 2018 until May 17, 2021. Mr. Hallal serves as an Advisor at MPM Asset Management, L.L.C. He served as the Executive Partner at MPM Capital. He served as the Chief Executive Officer and Director of Alexion Pharmaceuticals, Inc. from April 1, 2015 to December 12, 2016 and from September 2014 to December 12, 2016 respectively. He serves as Chairman of the Board at Iteos Therapeutics S.A. Mr. Hallal served as the Chief Operating Officer of Alexion Pharmaceuticals, Inc. from September 2014 to April 1, 2015. Mr. Hallal has been the Lead Independent Director of the Board of Directors of Seer, Inc. since March 2018. He served in various executive roles at Alexion Pharmaceuticals since June 2006 until December 2016. He served as the Chief Commercial Officer and Executive Vice President of Alexion Pharmaceuticals, Inc. from October 2012 to September 2014. He served as Senior Vice President of Global Commercial Operations at Alexion Pharmaceuticals, Inc. since May 2010. He served as a Senior Vice President of Commercial Operations, Americas of Alexion Pharmaceuticals, Inc. since November 2008. Mr. Hallal was responsible for all Commercial Functions in the U.S. Market, including marketing, sales and reimbursement/access. Mr. Hallal served as Senior Vice President of US Commercial Operations at Alexion Pharmaceuticals, Inc. and also served as its Vice President of US Commercial Operations since July 2006. He has extensive commercial experience in the pharmaceutical industry. Mr. Hallal served as Vice President for U.S. Commercial Operations of Alexion Pharmaceuticals from June 2006 to November 2007. Prior to Alexion, from April 2004 to June 2006, Mr. Hallal served as a Vice President of Sales at OSI Eyetech where he led the U.S. launch of the first-in-class anti-VEGF therapy, Macugen for age-related macular degeneration. From 2002 to 2004, Mr. Hallal served as Head of Sales at Biogen Incorporated. From 1988 to 1992, Mr. Hallal began his pharmaceutical career at The Upjohn Company as a sales Representative. In 1992, Mr. Hallal held various leadership positions at Amgen, focusing on the blockbuster brands Epogen, Neupogen, Neulasta and Aranesp in the hematology and oncology marketplace. More specifically from 1999 to 2002, he served as Sales Director of Southeast Oncology and then helped Amgen build its first dedicated hospital sales team. During this time, Mr. Hallal played an integral role in pre-launch planning and the launch of Aranesp and Neulasta. He has been a Member of the Board of Directors of Seer Biosciences, Inc. From 1998 to 1999, Mr. Hallal served as Amgen’s Director of Oncology National Accounts, where he played a significant role in developing key long-term Partnerships with the nation’s largest oncology practice management groups and physician group purchasing organizations. From 1992 to 1998, Mr. Hallal served in roles of escalating responsibility for the promotion of Epogen and Neupogen, including National Account Manager where he was responsible for forging relationships with many of the largest managed care organizations in the U.S. Mr. Hallal holds a B.A. in psychology from the University of New Hampshire.
Positions
- Company NameScholar Rock Holding CorporationStock CodeSRRKPositionCEO & Chairman of the BoardColleagues
- DLDavid L. HallalCEO & Chairman of the Board
- VSVikas SinhaCFO & Treasurer
- RKRobert Keith WoodsChief Operating Officer
- AKAkshay Krishnadas VaishnawPresident of R&D, Member of Scientific Advisory Board and Director
- EMErin MooreInterim Principal Financial & Accounting Officer
- KMKristina M. BurowIndependent Director
- JSJeffrey S. FlierIndependent Director & Member of Scientific Advisory Board
- JRJoshua ReedIndependent Director
- Company NameKalaris Therapeutics, Inc.Stock CodeKLRSPositionIndependent Chairman of the Board
